Thalagen™ is the brand name for EGT’s gene therapy treatment for beta thalassemia, also referred to as Cooley’s anemia. To date there is no curative therapy for thalassemia, a disease characterized by the cells of the bone marrow having an inability to produce normal hemoglobin.
Trichostatin A (TSA) was originally reported (1976) as a fungistatic antibiotic obtained from a culture broth of Streptomyces platensis. In 1987, its anti-proliferative activity was reported, and in 1990, TSA was found to cause an accumulation of acetylated histones in a variety of mammalian tumor
cell lines.
CG-1521 (7-phenyl-2, 4, 6-hepta-trienoyl hydroxamic acid) is an inhibitor of histone deacetylase (HDAC) in the final stages of pre-clinical development. The compound has been shown to inhibit cell proliferation of both solid and hematological cancer cells and has been extensively studied in neuroblastoma and prostate cancer models.
Federal Grant Awarded To Chicago BioMed Firm To Advance Research on Thalassemia, Among the World’s Largest Hereditary Disorder; Firm Has Potential “in Vitro” Cure
Errant Gene Therapeutics Awarded Maximum Level Grant for
Thalagen Treatment